COVID-19 vaccine effectiveness
(Randomized evidence)

Analyses are updated every Friday

Methods

Variants of concern

RCTs

Treatment comparisons

Trial Type Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Intervention 1 Intervention 2
NCT04495933
The University of Queensland; Syneos Health; CSIRO Manufacturing; Seqirus; Coalition for Epidemic Preparedness Innovations
Chappell K, Lancet, 2021

Full text
Commentary
Protein subunit

SARS-CoV-2 Sclamp 5-mcg D

SARS-CoV-2 Sclamp 15-mcg

SARS-CoV-2 Sclamp 45-mcg

SARS-CoV-2 Sclamp 45-mcg

Placebo

RCT
Phase 1
Healthy SARS-CoV-2 infection-free adults aged 18-55 at one center in Australia. N=120
Some concerns
Details

Full description

NCT04368988
Novavax
Formica N, medRxiv, 2021

Full text
Commentary
Commentary
Protein subunit

NVX-CoV2373

NVX-CoV2373 5mcg D0

25mcg NVX-CoV2373 D0/D21

25mcg NVX-CoV2373 D0

Placebo

RCT
Phase 2
Healthy adults (stable comorbidities and confirmed COVID-19 with mild symptoms permitted) aged 18-84 years at 17 centers in Australia and USA N=1288
Some concerns
Details

Full description

NCT04537208
Sanofi Pasteur, GlaxoSmithKline
Goepfert P, Lancet, 2021

Full text
Commentary
Protein subunit

CoV2 preS dTM LD + AFO3

CoV2 preS dTM LD + ASO3

CoV2 preS dTM HD + AFO3

CoV2 preS dTM HD + ASO3

CoV2 preS dTM HD

Placebo

RCT
Phase 1-2
Health adults aged 18 years and older and SARS-CoV-2 infection-free in 10 centres in the USA. N=271
Some concerns
Details

Full description

NCT04583995; EudraCT 2020-004123-16
Novavax
Heath P, N Engl J Med, 2021

Full text
Commentary
Protein subunit

NVX-CoV2373

Placebo

RCT
Phase 3
Adults 18 to 84 years old who were healthy or had stable chronic medical conditions with no history of COVID-19 at 33 centres in the UK. N=15187
Some concerns
Details

Full description

NCT04368988
Novavax
Keech C, N Engl J Med, 2020

Full text
Commentary
Protein subunit

25mcg NVX-D0/21

NVX-CoV2373

25mcg NVX/M1-D0/21

25mcg NVX/M1+Placebo-D0/2

Placebo

RCT
Phase 1
Healthy adult volunteers, SARS-CoV-2 infection-free and no history of SARS-CoV-2 infection in two centres in Australia. N=134
Some concerns
Details

Full description

ChiCTR2100045108
Guangdong Provincial Center for Disease Control and Prevention
Liao Y, Emerg Microbes Infec, 2021

Full text
Commentary
Protein subunit

V-01 10 mcg

V-01 25 mcg

V-01 50 mcg

Placebo

RCT
Phase 1
Healthy seronegative adults with no history of COVID-19 in a single center in China N=180
Some concerns
Details

Full description

NCT04530656
West China Hospital of Sichuan University
Meng F, Signal Transduct Tar, 2021

Full text
Commentary
Protein subunit

Sf9 cells vaccine

Sf9 cells vaccine

Sf9 cells vaccine

Placebo

RCT
Phase 1
Healthy adults with no history of COVID-19 in a single centre in China N=168
Some concerns
Details

Full description

NCT04683484
Nanogen Pharmaceutical Biotechnology JSC
Nguyen T, medRxiv, 2021

Full text
Commentary
Commentary
Protein subunit

Nanocovax 25 mcg

Nanocovax 50 mcg

Nanocovax 75 mcg

RCT
Phase 1
Healthy HIV-negative and seronegative adults at a single center in Vietnam N=60
Some concerns
Details

Full description

NCT04683484
Nanogen Pharmaceutical Biotechnology JSC
Nguyen T, medRxiv, 2021

Full text
Commentary
Commentary
Protein subunit

Nanocovax 25 mcg

Nanocovax 50 mcg

Nanocovax 75 mcg

Placebo

RCT
Phase 2
Healthy HIV-negative and seronegative adults at 2 centers in Vietnam N=560
Low
Details

Full description

NCT04405908
Clover Biopharmaceuticals, Chengdu, China
Richmond P, Lancet, 2021

Full text
Commentary
Protein subunit

SCB-2019 3 mcg

SCB-2019 3 mcg + AS03

SCB-2019 3 mcg + CpG/Alum

SCB-2019 9 mcg

SCB-2019 9 mcg + AS03

SCB-2019 9 mcg + CpG/Alum

SCB-2019 30 mcg

SCB-2019 30 mcg + AS03

SCB-2019 30 mcg + CpG/Alu

Placebo

RCT
Phase 1
Healthy SARS-CoV-2 serology/DNA negative adults aged 18-75 years at one study center in Australia N=151
Low
Details

Full description

NCT04527575
EpiVac LLC ; State Scientific Center of Virology and Biotechnology “Vector” of Rospotrebnadzor
Ryzhikov AB, Infektsiia Immun, 2021

Full text
Commentary
Protein subunit

EpiVacCorona

Placebo

RCT
Phase 2
Healthy adult SARS-CoV-2 infection-free volunteers in a single center in Russia. N=86
Some concerns
Details

Full description

NCT04533399; PACTR202009726132275
Novavax
Shinde V, N Engl J Med, 2021

Full text
Commentary
Protein subunit

NVX-CoV2373

Placebo

RCT
Phase 2a/b
HIV-negative adults (18 to 84 years) and medically stable HIV-positive adults (18 to 64 years) at 16 sites in South Africa N=4406
Some concerns
Details

Full description

NCT04466085
Institute of Microbiology, Chinese Academy of Sciences ; Anhui Zhifei Longcom Biopharmaceutical Co., Ltd
Yang S, Lancet, 2021

Full text
Commentary
Protein subunit

ZF2001 25 mcg 2 doses

ZF2001 50 mcg 2 doses

ZF2001 25 mcg 3 doses

ZF2001 50 mcg 3 doses

Placebo

RCT
Phase 2
Healthy SARS-CoV-2 infection-free adults aged 18-59 at 1 center in China N=900
Low
Details

Full description

NCT04445194
Institute of Microbiology, Chinese Academy of Sciences ; Anhui Zhifei Longcom Biopharmaceutical Co., Ltd
Yang S, Lancet, 2021

Full text
Commentary
Protein subunit

ZF2001 25 mcg 3 doses

ZF2001 50 mcg 3 doses

Placebo

RCT
Phase 1
Healthy SARS-CoV-2 infection-free adults aged 18-59 at 2 centers in China N=50
Some concerns
Details

Full description